About Zembrace® SymTouch®

Sumatriptan is proven efficacious with a well defined safety profile.1

When timing is everything

Whether it’s waking up with a migraine or experiencing rapid-onset pain, patients want relief—fast.1,2

Fast1,2

Patients may begin to feel migraine pain relief in as little as 10 minutes (17% of patients vs. 5% for placebo).*

Powerful1

~50% of patients experienced migraine pain relief 30 minutes after administration (47% vs. 15% for placebo).*

Simple

A convenient, ready-to-use auto-injector with:

  • A concealed 29 G needle3
  • A discreet, compact design1
  • No refrigeration needed†

60% of patients experienced migraine pain relief 2 hours after administration (vs. 21% for placebo).1 Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).

*Time to onset and degree of pain relief varies by patient.
†Store between 68°F and 77°F. Excursions permitted between 59°F and 86°F.

Zembrace® SymTouch® offers the lowest dose in a sumatriptan auto-injector.3

Minutes matter

Proportion of patients with migraine pain relief by time with a 3 mg dose of sumatriptan injection (n=30).1 ‡

3 mg dose of sumatriptan
Placebo
10 mins
17%
5%
30 mins
47%
15%
60 mins
57%
24%
2 hours
60%
21%

‡Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine treated, reconsider the diagnosis before Zembrace® SymTouch® is administered to treat subsequent attacks. Zembrace® SymTouch® is not indicated for the prevention of migraine attacks, and is contraindicated in patients with a history of hemiplegic or basilar migraines.

Committed to providing more

Upsher-Smith Laboratories, LLC takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.

Zembrace® SymTouch® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.

References:

  1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276
  3. Data on file. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2021.